Advertisement

Canadian Journal of Public Health

, Volume 104, Issue 3, pp e235–e239 | Cite as

Completion Rates of Treatment for Latent Tuberculosis Infection in Quebec, Canada From 2006 to 2010

  • Paul Rivest
  • Maria-Constanza Street
  • Robert Allard
Quantitative Research
  • 1 Downloads

Abstract

Objective

Treatment of latent TB infection (LTBI) in high-risk populations has been identified as a priority activity for reducing TB incidence. Treatment completion rates are usually far from the 80% target. The objective of this study was to evaluate the proportion of individuals who obtained enough medication for standard LTBI treatment.

Methods

Using the Régie de l’assurance maladie du Québec database, we extracted data on all prescriptions filled as part of the free anti-tuberculosis medication program. We calculated the proportion of patients who had obtained at least 270 doses among patients who had started treatment with isoniazid (INH), and the proportion of patients who had obtained at least 120 doses among patients who had started treatment with rifampin (RMP).

Results

Among the 2,895 patients who had started INH, 907 (31.3%) obtained at least 270 doses. Among the 373 patients who had started RMP, 242 (64.9%) obtained at least 120 doses. Women were more likely to stop INH treatment before acquiring 270 doses of the medication than men (hazard ratio [HR] = 1.08; 95% confidence interval [CI]: 1.01–1.17).

Conclusion

Only 31.3% of patients who started treatment with INH had procured at least 270 doses. Completion rates are far below target values.

Key words

Tuberculosis isoniazid treatment compliance adherence 

Résumé

Objectif

Traiter l’infection tuberculeuse latente (ITL) dans les populations à haut risque représente une activité importante pour réduire le fardeau d’incidence de la tuberculose. Les taux d’achèvement du traitement demeurent en deçà de l’objectif habituel de 80 %. Le but de cette étude était d’évaluer la proportion des personnes qui se sont procuré suffisamment de médicaments pour le traitement de l’ITL.

Méthode

À partir du fichier de données de la Régie de l’assurance maladie du Québec, nous avons obtenu toutes les ordonnances remplies dans le cadre du Programme de gratuité des médicaments pour la tuberculose. Nous avons calculé, parmi des patients qui ont été traités avec isoniazide (INH), la proportion de ceux qui se sont procuré au moins 270 doses. Nous avons également calculé, parmi des patients qui ont été traités avec rifampine (RMP), la proportion de ceux qui se sont procuré au moins 120 doses.

Résultats

Parmi les 2 895 patients qui ont été traités avec l’INH, 907 (31,3 %) se sont procuré au moins 270 doses. Parmi les 373 patients qui ont commencé un traitement préventif à la RMP, 242 (64,9 %) se sont procuré au moins 120 doses. Les femmes avaient plus de chances d’abandonner le traitement avant de s’être procuré au moins 270 doses d’INH que les hommes (Ratio de taux [RT] = 1,08; Intervalle de confiance [IC] à 95 %: 1,01–1,17).

Conclusion

Seulement 31,3 % des patients qui ont été traités avec l’INH se sont procuré au moins 270 doses. Les taux d’achèvement sont bien en deçà des taux habituellement visés.

Mots Clés

tuberculose isoniazide traitement observance fidélité au traitement 

References

  1. 1.
    Public Health Agency of Canada. Tuberculosis in Canada 2010 - Pre-release. Ottawa, ON: Ministry of Public Works and Government Services, 2011. Available at: https://doi.org/www.publichealth.gc.ca/tuberculosis (Accessed April 2, 2012).Google Scholar
  2. 2.
    Public Health Agency of Canada. Guidance for Tuberculosis Prevention and Control Programs in Canada. Ottawa: Ministry of Public Works and Government Services, 2011.Google Scholar
  3. 3.
    Public Health Agency of Canada. Canadian Tuberculosis Standards. Ottawa: Ministry of Public Works and Government Services, 2007. Available at: https://doi.org/www.phac-aspc.gc.ca/tbpc-latb/pubs/pdf/tbstand07e.pdf (Accessed April 2, 2012).Google Scholar
  4. 4.
    Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008;12(11):1235–54.PubMedGoogle Scholar
  5. 5.
    Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: Outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003;7(Suppl 3):S384–S390.PubMedGoogle Scholar
  6. 6.
    Reichler MR, Reves R, Bur S, Ford J, Thompson V, Mangura B, et al. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 2002;95:414–20.CrossRefGoogle Scholar
  7. 7.
    Anger HA, Proops D, Harris TG, Li J, Kreiswirth BN, Shashkina E, Ahuja SD. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis 2012;54:1287–95.CrossRefGoogle Scholar
  8. 8.
    Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: Implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186(3):273–79.CrossRefGoogle Scholar
  9. 9.
    Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004;8:76–82.PubMedGoogle Scholar
  10. 10.
    Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of Rifampin for 4 months versus Isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445–49.CrossRefGoogle Scholar
  11. 11.
    Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of Rifampin. Chest 2006;130:1712–17.CrossRefGoogle Scholar
  12. 12.
    Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with Rifampin vs Isoniazid for treatment of latent tuberculosis: A retrospective study. Arch Intern Med 2006;166:1863–70.CrossRefGoogle Scholar
  13. 13.
    Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137(2):401–9.CrossRefGoogle Scholar
  14. 14.
    Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011;183(3):E173–E179.CrossRefGoogle Scholar
  15. 15.
    Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of Rifapentine and Isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155–66.CrossRefGoogle Scholar
  16. 16.
    Centers for Disease Control and Prevention. Recommendations for use of an Isoniazid-Rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR 2011;60(48):1650–53.Google Scholar

Copyright information

© The Canadian Public Health Association 2013

Authors and Affiliations

  • Paul Rivest
    • 1
    • 2
  • Maria-Constanza Street
    • 1
  • Robert Allard
    • 1
    • 3
  1. 1.Direction de santé publique de Montréal, Agence de la santé et des services sociauxMontréalCanada
  2. 2.Département de médecine sociale et préventiveUniversité de MontréalMontréalCanada
  3. 3.Department of Epidemiology, Biostatistics and Occupational HealthMcGill UniversityMontréalCanada

Personalised recommendations